Natera Inc. Common Stock (NTRA)
Stock · NASDAQ · Health Care
$326.26as of 8/28/2026
Price chart
Open in TradingViewActive signals
High Beta28.6%
Support level
$197.31
Industry
Medical Specialities
About NTRA
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profili…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 6,135
- Website
- www.natera.com/
Fundamentals
- 1-day range
- $325.66$339.3
- Market cap
- $38.72B
- P/E (trailing)
- —
- P/E (forward)
- -3657.62
- EPS (trailing)
- $-1.37
- Dividend yield
- —
- Beta
- 1.58
- Avg. volume
- 1.43M
52-week range
$157.43$343.18
Next earnings: November 5, 2026 · EPS estimate $-0.24After Closeconfirmed
How Natera Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
21 analyst ratings
Buy 87%
Hold 13%
Sell 0%
1-year price forecast
High
$375
+14.9%
Median
$348
+6.7%
Low
$280
-14.2%
Natera Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NTRANatera Inc. Common Stock$326.47▼ 3.61%Market cap $38.72BP/E —$157.43$343.18
- CNCCentene Corporation Common Stock$64.77▼ 0.86%Market cap $31.50BP/E —$28.24$69.36
- ILMNIllumina Inc. Common Stock$215.65▼ 5.29%Market cap $29.98BP/E 34.73$88$231.81
- GHGuardant Health Inc. Common Stock$161.76▼ 4.01%Market cap $21.31BP/E —$53.4$176.58
- MOHMolina Healthcare Inc Common Stock$199.88▲ 0.57%Market cap $10.17BP/E 1249.59$121.06$244.89
- OSCROscar Health Inc. Class A Common Stock$30.47▲ 1.38%Market cap $9.27BP/E 16.85$10.69$33.55
- BLLNBillionToOne Inc. Class A Common Stock$93.27▼ 1.98%Market cap $6.32BP/E 117.67$61.96$150.44
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NTRA Natera Inc. Common Stock | $38.72B | — | $326.47 | ▼ 3.61% | $157.43$343.18 |
| CNC Centene Corporation Common Stock | $31.50B | — | $64.77 | ▼ 0.86% | $28.24$69.36 |
| ILMN Illumina Inc. Common Stock | $29.98B | 34.73 | $215.65 | ▼ 5.29% | $88$231.81 |
| GH Guardant Health Inc. Common Stock | $21.31B | — | $161.76 | ▼ 4.01% | $53.4$176.58 |
| MOH Molina Healthcare Inc Common Stock | $10.17B | 1249.59 | $199.88 | ▲ 0.57% | $121.06$244.89 |
| OSCR Oscar Health Inc. Class A Common Stock | $9.27B | 16.85 | $30.47 | ▲ 1.38% | $10.69$33.55 |
| BLLN BillionToOne Inc. Class A Common Stock | $6.32B | 117.67 | $93.27 | ▼ 1.98% | $61.96$150.44 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Natera Announces Signatera Collaboration With Angiex To Develop A Portfolio Of Nuclear-Delivered Antibody-Drug Conjugatesbenzinga · 8/27/2026
- Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine AdvanceSeekingAlpha · 8/20/2026
- Natera: Even 30% Annual Growth Through 2030 Doesn't Support $310 Per ShareSeekingAlpha · 8/20/2026
- Here's How Much $1000 Invested In Natera 10 Years Ago Would Be Worth TodayBenzinga · 8/18/2026
- Citigroup Maintains Buy on Natera, Raises Price Target to $365Benzinga · 8/13/2026
- Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference TranscriptSeekingAlpha · 8/13/2026
- Piper Sandler Maintains Overweight on Natera, Raises Price Target to $363.5Benzinga · 8/12/2026
- Stephens & Co. Maintains Overweight on Natera, Raises Price Target to $350Benzinga · 8/12/2026
- Guggenheim Maintains Buy on Natera, Raises Price Target to $360Benzinga · 8/12/2026
Insider Activity
Insider Actions →Acquired
0
Disposed
19.0K
- Jonathan Sheena · August 10, 2026 · Sale6.0K @ $325.32
- Jonathan Sheena · August 7, 2026 · Sale489 @ $320.9
- Jonathan Sheena · August 7, 2026 · Sale100 @ $308.4
- Jonathan Sheena · August 7, 2026 · Sale200 @ $317.97
- Jonathan Sheena · August 7, 2026 · Sale5.1K @ $316.61
- Jonathan Sheena · August 7, 2026 · Sale600 @ $315.32
- Jonathan Sheena · August 7, 2026 · Sale850 @ $314.25
- Jonathan Sheena · August 7, 2026 · Sale900 @ $313.07
- Jonathan Sheena · August 7, 2026 · Sale400 @ $310.23
- Matthew Rabinowitz · August 7, 2026 · Sale2.0K @ $320.9
- Michael Burkes Brophy · August 4, 2026 · Sale478 @ $274.22
- John Fesko · August 3, 2026 · Sale295 @ $267.99
- Solomon Moshkevich · August 3, 2026 · Sale128 @ $268.7
- Solomon Moshkevich · August 3, 2026 · Sale1.2K @ $267.79
- Solomon Moshkevich · August 3, 2026 · Sale192 @ $265.28
Institutional Ownership
March 31, 2026
- Total shares held
- 114.39M
- Total value held
- $19.05B
- Institutional holders
- 751
Top holders this quarter
- Unknown12.18M
- Unknown10.68M
- Unknown6.01M
- Unknown4.77M
- Unknown3.42M
- Unknown3.21M
- Unknown3.06M
- Unknown2.78M
- Unknown2.55M
- Unknown2.54M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 28, 2026
NTRA partners with Angiex on ADCs, valuation questioned.. Natera has announced a collaboration with Angiex to develop a portfolio of nuclear-delivered antibody-drug conjugates using its Signatera platform. This partnership focuses on expanding the company's offerings in the biotechnology sector. At the same time, a separate report suggests that the company's current growth may not justify its current levels, highlighting a divide in market expectations.